EarningsQ2 2026 Earnings Report
MX:LONNN Q2 2026 EPS Results
Actual EPS$169.78
Consensus EPS$180.99
Beat/MissMissed by -$11.21
One Year Ago EPS$156.25
MX:LONNN Q2 2026 Revenue Results
Actual Revenue$70.20B
Expected Revenue$70.60B
Beat/MissMissed by -$404.30M
YoY Revenue Growth-5.65%
Earnings Announcement Details
QuarterQ2 2026
Date07/22/2026
TimeBefore Open
Conference CallWednesday, July 22, 2026
MX:LONNN Upcoming Earnings
Lonza Group Ltd's next earnings date is estimated for January 27, 2027, based on past reporting schedules.
Q2 2026 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a clearly positive operational and financial story: strong organic top-line growth (16% CER), material margin expansion (CORE EBITDA margin +4.4pp to 34.8%), markedly improved free cash flow, platform-level recovery and high-margin performance in Advanced Synthesis, and completion of the strategic transformation to a pure-play CDMO with a CHF 2.3bn divestment. Management upgraded margin guidance while reconfirming full-year CER sales growth of 11%-12% and outlined disciplined, high-return investments. Key near-term headwinds are FX translation effects, H2 phasing (including a planned Vacaville shutdown), elevated trade working capital, and expected margin normalization in H2 for some units after an exceptionally strong H1. Overall, the positives—robust organic growth, margin and cash-flow improvements, strategic clarity and targeted capacity investments—substantially outweigh the operational timing and FX headwinds.Company Guidance
Strong top-line growth
H1 2026 sales of CHF 3.4 billion, organic CER sales growth of 16% versus H1 2025 (entirely organic), and year-to-date momentum across all businesses.
Significant margin expansion
CORE EBITDA increased to CHF 1.2 billion (up 27.4% vs H1 2025) producing a CORE EBITDA margin of 34.8%, a 4.4 percentage-point improvement year-over-year; full-year CORE EBITDA margin outlook upgraded to 33%-34%.
Material free cash flow improvement
Free cash flow improved to CHF 426 million in H1 2026 from CHF 116 million in H1 2025 (approximately +CHF 310 million), reflecting stronger earnings and somewhat lower CapEx.
Broad-based platform performance
All three business platforms delivered double-digit CER growth: Integrated Biologics +10% (sales CHF 1.87bn), Advanced Synthesis +27.7% (sales CHF 834m), Specialized Modalities +22.6% (sales CHF 553m).
Outstanding performance in Advanced Synthesis
Advanced Synthesis CORE EBITDA margin increased to ~48.1% (up 6.8 percentage points) driven by strong small-molecule and bioconjugate demand, favorable mix and operating leverage.
Specialized Modalities margin recovery
Specialized Modalities CORE EBITDA margin rose to 28% (up ~10.7 percentage points) driven by microbial recovery, bioscience growth and improved Cell & Gene operations.
Strategic transformation completed and accretive divestment
Transformation into a pure‑play CDMO advanced with the agreement to divest Capsules & Health Ingredients (CHI) for an enterprise value of CHF 2.3 billion, expected to close before year-end 2026.
Targeted growth investments and capacity expansion
Announced ADC-related investments: multipurpose highly potent payload linker suites in Visp (ramp 2029) and a second commercial ADC aseptic fill line in Stein (ramp ~2030) with anchor customer; committed >CHF 7bn organic CapEx to 2030 with IRR and ROIC thresholds (IRR ≥15%, peak ROIC ≥30%).
Improving returns
ROIC increased to ~13.2% (almost +3 percentage points vs prior period) and management indicates ROIC roughly ~2x WACC today, with scope for further improvement as margins and utilization increase.
MX:LONNN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed